Management of Initial and Recurrent C. difficile Infections

Managing Recurrent and Hypervirulent CDI Program Image
Gain expert insights on the latest data and guidance for managing challenging C. difficile infections in this case-focused, CME-certified Interactive Virtual Presentation.
CiarĂ¡n P. Kelly, MD
Released: November 21, 2018 Expiration: No longer available for credit

Related Content

High-dose trivalent influenza vaccine comparable to standard-dose quadrivalent vaccine in deaths or cardiopulmonary hospitalizations in high-risk CV disease; AHA results reported by CCO

Released: November 20, 2020

Vericiguat VICTORIA subgroup analysis from AHA, as reported by CCO

Released: November 18, 2020

Ferric carboxymaltose reduced risk of subsequent hospitalization in iron-deficient acute heart failure: AFFIRM-AHF data from AHA 2020, by CCO

Released: November 18, 2020

Omecamtiv mecarbil reduced time to first heart failure event or cardiovascular death in patients with heart failure with reduced ejection fraction: GALACTIC-HF data from AHA 2020 as reported by CCO

Released: November 16, 2020
Provided by Postgraduate Institute for Medicine
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)

Supported by an educational grant from
Merck & Co., Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.